Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
Top brand choice
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Gammagard Liquid is a ready-to-use, sterile solution of Immunoglobulin (Human) indicated for the treatment of primary humoral immunodeficiency (PI) and multifocal motor neuropathy (MMN). It is derived from pooled human plasma and contains a broad spectrum of IgG antibodies. Patients seeking to buy Gammagard benefit from its proven efficacy in reducing infections associated with immunodeficiency and managing progressive neuromuscular symptoms in MMN. This formulation is suitable for intravenous (IV) or subcutaneous (SC) administration, providing flexible dosing options based on individual patient needs. Those considering Gammagard Liquid should consult their healthcare provider to discuss the appropriate therapeutic regimen and monitor Gammagard cost relative to insurance and infusion services.
| Fact Table | |
|---|---|
| Formula | Not applicable (biologic product – mixture of IgG antibodies) |
| License | FDA approved |
| Bioavailability | ~100% (intravenous); lower for subcutaneous |
| Legal status | Prescription only |
| Chemical Name | Immunoglobulin G (Human) |
| Elimination half-life | Approximately 21 to 28 days |
| Dosage (Strength) | 10% solution (100 mg/mL) |
| Pregnancy | Use only if clearly needed; consult healthcare provider |
| Brands | Gammagard Liquid |
| Protein binding | High (IgG binds to Fc receptors and antigens) |
| PubChem CID | Not available (biologic product) |
| MedlinePlus | a605050 |
| ChEBI | 36080 |
| ATC code | J06BA02 |
| DrugBank | DB00028 |
| KEGG | D04570 |
| Routes of administration | Intravenous (IV), Subcutaneous (SC) |
Gammagard Liquid should be administered under the supervision of a healthcare professional experienced in immunoglobulin therapy. For IV use, the recommended dose for patients with PI typically ranges from 300 to 600 mg/kg body weight every 3 to 4 weeks. For SC use, a loading dose may be administered over several days, followed by weekly maintenance doses adjusted according to serum IgG levels and clinical response. Patients with MMN generally receive doses based on individual response and tolerability, with infusions repeated every 2 to 4 weeks. Infusion rates should be gradually increased as tolerated, with close observation during administration.
Each milliliter of Gammagard Liquid contains 100 mg of immunoglobulin G (IgG). The solution may also include small amounts of glycine as a stabilizer and water for injection. Gammagard Liquid is preservative-free and contains no added sugars, latex, or mercury.
Before starting Gammagard Liquid, clinicians should assess the patient's renal function and thrombotic risk factors. Use caution in individuals with diabetes mellitus, volume overload, or a history of renal impairment. Ensure patients are well hydrated before administration. Monitoring is essential for patients receiving high doses or rapid infusions, particularly the elderly or those with comorbid conditions. As with all blood-derived products, there is a minimal risk of transmitting infectious agents, although rigorous screening and viral inactivation steps are applied.
Gammagard Liquid is contraindicated in individuals with a history of anaphylactic or severe systemic reactions to human immunoglobulin preparations. It is also contraindicated in patients with IgA deficiency who have developed antibodies against IgA, as they are at increased risk of hypersensitivity reactions.
Common side effects associated with Gammagard Liquid may include:
Severe but rare side effects may include anaphylaxis, aseptic meningitis, hemolysis, renal dysfunction, and thromboembolic events. Immediate medical attention is advised if symptoms of a serious allergic reaction occur.
What is GAMMAGARD LIQUID?
GAMMAGARD LIQUID is an immune globulin therapy made from human plasma. It contains immunoglobulin G (IgG) antibodies that help protect against infections. It is administered either intravenously (IV) or subcutaneously (SubQ), depending on the condition being treated.
What conditions is it used to treat?
GAMMAGARD LIQUID is approved for:
How is it administered?
Your healthcare provider will determine the appropriate method and schedule based on your specific condition and response to treatment.
What is the typical dosage?
Dosage varies based on the condition:
Dosage and infusion rates should be individualized based on patient response and tolerance.
Who should not use GAMMAGARD LIQUID?
Do not use GAMMAGARD LIQUID if you:
What precautions should be taken?
How should it be stored?
